Precision peptide research for the next decade of biology.

Ceretropic Labs develops and distributes high-purity research peptides for laboratory applications across Europe. We focus on compounds with meaningful clinical signal and underserved supply.

Purity standard ≥ 99% HPLC
Formulation Phosphate buffered
Distribution EU + Balkans
First launch GHK-Cu, Q4 2026
What we do

Research peptides, done to a clinical standard.

Three problems define the research peptide market: purity claims nobody verifies, formulation shortcuts that degrade product before it reaches the lab, and supply inconsistency that breaks research continuity. Ceretropic Labs addresses each one.

01

Verified purity

Every batch undergoes HPLC analysis with the certificate attached to the vial lot number. No batch ships without the data available on request.

02

Stabilized formulation

Phosphate buffer at pH 6.5, phenol preservative, polysorbate stabilizer. The same formulation platform used in branded GLP-1 pens. Extended post-reconstitution stability compared to plain bacteriostatic water.

03

Batch consistency

Single synthesis partner, standardized QC protocol, lot numbering that traces back to specific production runs. Research continuity across multiple orders.

Research areas

Four focus categories, one quality standard.

Active

Regenerative

Copper-peptide complexes and tissue-repair compounds. First launch: GHK-Cu at pharmaceutical-grade formulation standards.

Read more →
Pipeline

Metabolic

GLP-1 class compounds including retatrutide, tirzepatide, and semaglutide. Launch target: Q1 2027, distribution through verified partners.

Read more →
Pipeline

Longevity

Mitochondrial peptides (MOTS-c, SS-31), telomere-pathway compounds (Epithalon), and senolytic research tools.

Read more →
Pipeline

Healing & recovery

BPC-157, TB-500, and the classic healing stack with full documentation on reconstitution and storage.

Read more →
Distribution

We work through specialised regional partners.

Ceretropic Labs product reaches researchers through distribution partners who handle local-market logistics, documentation, and language support. Current and upcoming partners:

  • ghkcu.rs — Serbian market, GHK-Cu Official formulation. Active since Q4 2026.
  • Additional regional partners — in evaluation for Croatian, Slovenian, and broader EU markets through 2027.
Research use only. All Ceretropic Labs products are developed and distributed for laboratory research purposes exclusively. Not for human or veterinary consumption, diagnosis, or treatment. Not approved by EMA, FDA, HALMED, or any national regulatory body for medical use.